Immunosuppressants - New Zealand | Statista Market Forecast

In New Zealand, the revenue in the Immunosuppressants market is forecasted to reach NZ US$47.82m by 2024.
It is expected to witness a steady annual growth rate (CAGR 2024-2029) of 15.31%, leading to a market volume of NZ US$97.47m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$35.47bn in 2024.
New Zealand's immunosuppressant market is witnessing a surge in demand due to the increasing prevalence of autoimmune diseases in the country.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The Immunosuppressants market in New Zealand has been experiencing steady growth in recent years.

Customer preferences: Patients in New Zealand who require immunosuppressant medications generally have chronic conditions that require long-term treatment. As such, they prefer medications that are effective and have minimal side effects. Additionally, there is a growing preference for medications that are easy to administer, such as those that can be taken orally.

Trends in the market: One trend in the Immunosuppressants market in New Zealand is the increasing use of biologic drugs. These drugs, which are derived from living organisms, have shown to be effective in treating a variety of conditions, including autoimmune diseases. Another trend is the use of combination therapies, where multiple medications are used together to improve treatment outcomes. This approach is becoming more common as healthcare providers seek to tailor treatment plans to individual patients.

Local special circumstances: New Zealand has a publicly funded healthcare system, which means that the government plays a significant role in determining which medications are available to patients. This can impact the availability and pricing of immunosuppressant medications. Additionally, there is a strong focus on reducing healthcare costs in New Zealand, which can limit the availability of newer, more expensive medications.

Underlying macroeconomic factors: The New Zealand economy has been growing steadily in recent years, which has led to increased healthcare spending. However, the government is still focused on reducing healthcare costs, which can impact the availability of certain medications. Additionally, there is a growing aging population in New Zealand, which is driving demand for immunosuppressant medications.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.